Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

• Market Cap: $1.65B
• Dividend Yield: N/A
• Average Volume (3M): 1.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -100.34%
• EPS Growth: 52.85%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 109,819,570
• 10 Day Avg. Volume: 1,493,358
• 30 Day Avg. Volume: 1,564,888
• PEG Ratio: <0.01
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 2.95
• P/FCF Ratio: -1.53
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: -1.40K
• Enterprise Value/Gross Profit: -45.03
• Enterprise Value/Ebitda: -6.05
• 1Y Price Target: $20.22
• Price Target Upside: 34.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.54
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $14.00 ▼(-6.67% Downside)

Amylyx Pharmaceuticals' overall stock score is primarily impacted by its financial challenges, including declining revenues and operational losses. The technical analysis shows some short-term bullish momentum, but the valuation remains unattractive due to negative earnings. The earnings call provides a positive outlook with a strong cash position and progress in drug development, although delays in key trials present risks.

Positive Factors

Strong Cash Position

A robust cash position provides financial stability and flexibility to fund ongoing R&D and operational activities, supporting long-term growth.

FDA Breakthrough Therapy Designation

This designation can expedite the development and review process, potentially accelerating time to market and enhancing competitive positioning.

Decrease in Operating Expenses

Reduced operating expenses improve financial efficiency, allowing more resources to be allocated to strategic initiatives and R&D.

Negative Factors

Declining Revenue

A sharp decline in revenue growth can hinder the ability to fund operations and innovation, posing a risk to long-term sustainability.

Operational Losses

Sustained operational losses can erode financial health, limiting the company's ability to invest in growth and respond to market changes.

Cash Flow Challenges

Persistent cash flow issues can strain financial resources, affecting the company's ability to sustain operations and invest in future growth.

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, with a primary emphasis on conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The company is committed to advancing its lead product, AMX0035, which aims to slow the progression of neurodegenerative disorders by targeting multiple pathways involved in cellular stress and neuroinflammation. Through its scientific expertise and dedication to addressing unmet medical needs, Amylyx is positioned at the forefront of neurotherapeutics.

How the Company Makes Money

Amylyx Pharmaceuticals generates revenue primarily through the commercialization of its therapeutic products, particularly AMX0035, which has received regulatory approval for use in ALS patients. The company may also explore partnerships with larger pharmaceutical firms for co-development or licensing agreements to expand its product offerings and market reach. Additionally, revenue can be supplemented through grants and funding from governmental and non-governmental organizations aimed at fostering innovation in the biotech sector. As Amylyx progresses through clinical trials and achieves regulatory milestones, it may also benefit from milestone payments from partners, further contributing to its earnings.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Amylyx Pharmaceuticals is facing significant financial challenges, with declining revenues and substantial operational losses reflected in negative profit margins. The balance sheet shows a relatively low level of debt and a strong equity ratio, although historical negative equity points to potential financial instability. Cash flow analysis reveals persistent cash generation issues, which could impact future operational sustainability.

Income Statement

The company's revenue showed a significant decrease from 2023 to 2024, indicating a revenue growth rate of -77.05%. Despite having a gross profit margin of 51.76% in 2024, the net profit margin was highly negative at -345.20%, reflecting substantial operational losses. The EBIT and EBITDA margins were also negative, highlighting ongoing profitability challenges.

Balance Sheet

Amylyx Pharmaceuticals maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt. However, the company has a strong equity ratio of 85.10%, indicating that a majority of the assets are financed by shareholders' equity. Despite this, the company has consistently reported negative equity in previous years, pointing to financial instability risks.

Cash Flow

The company experienced a decline in free cash flow from 2023 to 2024, with a negative growth rate of -1671.46%. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. This indicates ongoing cash flow challenges, as the company is not generating sufficient cash from operations to cover its expenses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-665.00K	87.37M	380.79M	22.23M	0.00	650.00K
Gross Profit	-20.66M	45.22M	355.35M	19.24M	0.00	-23.94M
EBITDA	-153.71M	-290.98M	39.89M	-200.85M	-82.64M	-39.00M
Net Income	-149.28M	-301.74M	49.27M	-198.38M	-87.93M	-42.28M
Balance Sheet
Total Assets	362.74M	193.63M	517.45M	391.45M	105.61M	14.10M
Cash, Cash Equivalents and Short-Term Investments	343.99M	176.50M	371.36M	346.94M	96.12M	12.88M
Total Debt	5.93M	1.98M	4.24M	6.28M	0.00	1.43M
Total Liabilities	30.75M	28.87M	84.02M	50.85M	256.78M	80.83M
Stockholders Equity	332.00M	164.76M	433.43M	340.61M	-151.17M	-66.72M
Cash Flow
Free Cash Flow	-154.52M	-167.80M	10.68M	-182.40M	-75.15M	-36.85M
Operating Cash Flow	-154.45M	-167.65M	11.92M	-179.87M	-74.80M	-36.70M
Investing Cash Flow	49.55M	75.65M	92.05M	-238.99M	-46.41M	-151.00K
Financing Cash Flow	257.35M	348.00K	3.54M	431.79M	158.51M	46.82M

Amylyx Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Positive. The current price of 15 is above the 20-day moving average (MA) of 13.54, above the 50-day MA of 13.89, and above the 200-day MA of 7.96, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 62.13 is Neutral, neither overbought nor oversold. The STOCH value of 85.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMLX.

Amylyx Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	81 Outperform	$2.05B	11.20	25.93%	―	21.13%	50.86%
DNTH	55 Neutral	$1.32B	-10.20	-28.57%	―	-42.64%	-39.78%
AMLX	52 Neutral	$1.65B	―	-56.52%	―	-100.34%	52.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCRX	46 Neutral	$1.49B	―	―	―	45.38%	92.85%
PHVS	42 Neutral	$1.78B	―	-51.81%	―	―	-20.08%
BHVN	40 Underperform	$1.00B	―	-522.08%	―	―	18.76%

Amylyx Pharmaceuticals Inc Corporate Events

Amylyx Pharmaceuticals Reports Strong Q3 2025 Results

Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for neurodegenerative and endocrine diseases, with a notable emphasis on its investigational drug avexitide for post-bariatric hypoglycemia (PBH).

Amylyx Pharmaceuticals: Positive Earnings Call Highlights Progress and Challenges

Amylyx Pharmaceuticals’ recent earnings call exuded a generally positive sentiment, underscored by robust financial performance and significant progress across various programs. Despite these achievements, the call also highlighted some operational challenges, particularly the delay in the LUCIDITY trial enrollment. The urgency and unmet need in the post-bariatric hypoglycemia (PBH) market further emphasize the critical importance of avexitide’s development.

Amylyx Pharmaceuticals Advances Phase 3 Study for Post-Bariatric Hypoglycemia Treatment

Amylyx Pharmaceuticals, Inc. is conducting a Phase 3 study titled A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia. The study aims to assess the efficacy and safety of avexitide, a treatment for post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass, by measuring the reduction of hypoglycemic events.

Amylyx Pharmaceuticals Advances ALS Treatment with Promising Study Update

Study Overview: Amylyx Pharmaceuticals, Inc. is conducting a Phase 1 study titled Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis. The primary aim is to assess the safety and tolerability of AMX0114, a promising treatment for ALS, a debilitating neurodegenerative disease.

Amylyx Pharmaceuticals Announces $164 Million Stock Offering

On September 9, 2025, Amylyx Pharmaceuticals, Inc. announced an underwriting agreement to issue and sell 17,500,000 shares of its common stock at $10.00 per share, potentially raising approximately $164.0 million. The proceeds are intended for advancing avexitide commercial readiness, research and development, and general corporate purposes, with the offering expected to close on September 11, 2025.

The most recent analyst rating on (AMLX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.

Amylyx Pharmaceuticals Halts ORION Program for AMX0035

On August 27, 2025, Amylyx Pharmaceuticals announced the discontinuation of its ORION program for AMX0035 in adults with progressive supranuclear palsy, as the drug showed no significant differences compared to placebo in primary or secondary outcomes at Week 24. Consequently, the company will halt the Phase 2b trial and open-label extension, and will not proceed with the Phase 3 portion, although safety data remained consistent with previous studies.

The most recent analyst rating on (AMLX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.

Amylyx Pharmaceuticals Advances Phase 3 Study on Avexitide for Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals, Inc. is conducting a Phase 3 study titled A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia. The study aims to assess the efficacy and safety of avexitide, a treatment for post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery, by comparing it to a placebo. The significance lies in addressing PBH, a condition affecting patients post-surgery, by reducing hypoglycemic events.